Trials evaluating the benefit of PARP-inhibitors in breast cancer patients with mutations in HR-pathway genes other than BRCA1/2 have only included a very limited number of BRIP1-mutation patients and have not been able to confirm a PARP-inhibitor benefit for BRIP1-carriers [33, 34]. This evidence concerns the gene BRIP1 and breast cancer.